Maynard Um
-
-
-
-
-
-
-
Gain Therapeutics reports biomarker data from Parkinson's trial
-
-
-
-
-
-
-
Gain Therapeutics (GANX) PT Lowered to $9 at BTIG
-
-
-
-
-
-
-
Gain Therapeutics (GANX) Announces Formation of Clinical Advisory Board to Support Continued Advancement of Lead Drug Candidate GT-02287
-
-
-
-
-
-
-
Maxim Group Reiterates Buy Rating on Gain Therapeutics (GANX)
-
-
-
-
-
-
-
Gain Therapeutics (GANX) Announces the Completion of Dosing in the Multiple Ascending Dose of the Phase 1 Study of GT-02287
-
-
-
-
-
443,852 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

